Comprehensive post. An important detail to consider is the fact...

Comprehensive post.
An important detail to consider is the fact that we are 5 times as likely to succeed than usual drug developments.
That is not priced in, especially not after latest data.

Engagement with the world's leading business development partners and life science investors to establish the Company as a global leader in Ribonucleic Acid (RNA) therapeutics. The Company anticipates these engagements will create meaningful opportunities to more quickly progress and expand the Company's science and development programs.

No mention of being too small to engage, rather the opposite.
These statements were not made to simply attract short term investments, these were serious documentations of the ongoing discussions.
The company has no history to decorate its reporting or to balloon out its expectations.


The licence deal pursuit looks most fitting to me, 20 to 40 mil advance payments, some equity and CNS and kidney licence deal with payouts of about 500 mil per program,
amounting to 1.2 to 1.5 bil.
There is a reason why management is so excited about the CNS outlook, it is their
step up to the next level.

all IMO